Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Fritz Offner

Publications & Research Data

Awards & Distinctions

392 Results

2025

CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy

Bert LuyckxMaaike Van TrimpontFien DeclerckEleni StaessensAnnick VerheeSara T'SasSven EyckermanFritz OffnerPieter Van VlierbergheSteven Goossens et al.

A1 Journal Article in PHARMACOLOGICAL RESEARCH

Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment : process evaluation study of the CODE intervention in doctors and nurses working in ten acute hospital wards

Ruth PiersLet DillenKatrijn GoethalsAn LievrouwKaren VersluysAglaja De PauwCeline JacobsIne MoorsFritz OffnerAnja Velghe et al.

A1 Journal Article in PLOS ONE

Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment : the CODE stepped-wedge cluster randomized controlled trial (vol 50, pg 1635, 2024)

Dominique BenoitAglaja De PauwCeline JacobsIne MoorsFritz OffnerAnja VelgheNele Van Den NoortgatePieter DepuydtPatrick DruwéDimitri Hemelsoet et al.

Exploring the cell-free transcriptome as a biomarker source in non-Hodgkin lymphoma

Philippe DecruyenaereJo VandesompeleFritz Offner

Glofitamab in relapsed/refractory mantle cell lymphoma : results from a phase I/II study

Tycel Jovelle PhillipsCarmelo Carlo-StellaFranck MorschhauserEmmanuel BachyMichael CrumpMarek TrnenyNancy L. BartlettJan ZauchaTomasz WrobelFritz Offner et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Real-world evaluation of treatments and outcomes of follicular lymphoma in Belgium

Willem DaneelsGustaaf ClaeysYaro PreemFritz Offner

2024

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma : long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Philippe MoreauCyrille HulinAurore PerrotBertrand ArnulfKarim BelhadjLotfi BenboubkerSonja ZweegmanHelene CaillonDenis CaillotHerve Avet-Loiseau et al.

A1 Journal Article in LANCET ONCOLOGY

Characterizing the cell-free transcriptome in a humanized diffuse large B-cell lymphoma patient-derived tumor xenograft model for RNA-based liquid biopsy in a preclinical setting

Philippe DecruyenaereWillem DaneelsAnnelien MorlionKimberly VerniersJasper AnckaertJan TavernierFritz OffnerJo Vandesompele

A1 Journal Article in INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Characterizing the cell-free transcriptome in a humanized DLBCL patient-derived tumor xenograft model for RNA-based liquid biopsy in a preclinical setting

Philippe DecruyenaereJo VandesompeleWillem DaneelsFritz Offner

Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel : phase 2 ELARA 4-year update

Catherine ThieblemontMartin DreylingMichael J. DickinsonJoaquin Martinez-LopezArne KolstadJason ButlerMonalisa GhoshLeslie L. PopplewellJulio C. ChavezEmmanuel Bachy et al.

Clinical outcomes of patients with relapsed/refractory follicular lymphoma (R/R FL) treated with tisagenlecleucel : phase 2 ELARA 3-year follow-up

Stephen J. SchusterNathan Hale FowlerMichael DickinsonJoaquin Martinez-LopezArne KolstadJason ButlerMonalisa GhoshLeslie PopplewellJulio C. ChavezEmmanuel Bachy et al.

Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment : the CODE stepped-wedge cluster randomized controlled trial

Dominique BenoitAglaja De PauwCeline JacobsIne MoorsFritz OffnerAnja VelgheNele Van Den NoortgatePieter DepuydtPatrick DruwéDimitri Hemelsoet et al.

A1 Journal Article in INTENSIVE CARE MEDICINE

Daratumumab (DARA) plus bortezomib/ thalidomide/dexamethasone (D-VTd) followed by DARA maintenance in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM) : 6-year update of the phase 3 CASSIOPEIA study

Philippe MoreauCyrille HulinAurore PerrotBertrand ArnulfKarim BelhadjLotfi BenboubkerSonja ZweegmanHelene CaillonDenis CaillotHerve Avet-Loiseau et al.

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma : ELARA trial update

Martin DreylingNathan Hale FowlerMichael DickinsonJoaquin Martinez-LopezArne KolstadJason ButlerMonalisa GhoshLeslie PopplewellJulio C. ChavezEmmanuel Bachy et al.

A1 Journal Article in BLOOD

Englumafusp Alfa (CD19-4-1BBL) combined with glofitamab is safe and efficacious in patients with r/r B-NHL : extended follow up analysis of the dose-escalation part of Phase 1 Trial BP41072

Martin HutchingsMichael J. DickinsonGiuseppe GrittiCarmelo Carlo-StellaWilliam TownsendFrancesc BoschNancy L. BartlettGuillaume CartronHerve GhesquieresRoch Houot et al.

Epcoritamab induces deep responses in patients with Richter Transformation (RT) : primary results from the EPCORE CLL-1 trial

Arnon P. KaterAnn JanssensHerbert EradatFritz OffnerJose D. Sandoval-SusMazyar ShadmanChristian Bjorn PoulsenJacob Haaber ChristensenMeghan C. ThompsonMarcia Rios et al.

Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) : results from CLL expansion and optimization cohorts of Epcore CLL-1

Alexey DanilovBita FakhriFarrukh T. AwanHans Herluf BentzenHerbert A. EradatCarsten Utoft NiemannFritz OffnerChristian Bjorn PoulsenThor HoeyerMar Bellido et al.

Epcoritamab plus R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Yasmin KarimiPau AbrisquetaSven de VosMarcel NijlandFritz OffnerKojo Osei-BonsuAli RanaKimberly G. ArcherYaou SongRaul Cordoba et al.

Epcoritamab plus R-DHAX/C induces deep, durable responses in transplant-eligible patients with relapsed or refractory (R/R) diffuse large B- cell lymphoma (DLBCL), including high-risk disease

Pau AbrisquetaLorenzo FalchiMarcel NijlandSven de VosFritz OffnerAli RanaKimberly ArcherYaou SongKojo Osei-BonsuYasmin Karimi et al.

Epcoritamab with rituximab plus lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7

Leslie A. LoriLorenzo FalchiJoost S. P. VermaatGerardo MusuracaDavid BeladaMarcel NijlandJacob Haaber ChristensenFritz OffnerDaniela HoehnJennifer Marek et al.

Exploring the cell-free transcriptome as biomarker source in IgM gammopathies : new insights from the Fondazione Italiana Linfomi 'BIO-WM' trial

Philippe DecruyenaereDaniela DrandiKimberly VerniersSimone RagainiJasper AnckaertVeronica PeriElisa GenuardiFederica CavalloLuigi MarcheselliIrene Dogliotti et al.

Final analysis of the RESONATE-2 study : up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

Jan BurgerPaul BarrTadeusz RobakCarolyn OwenAlessandra TedeschiAnita SarmaPiers E. M. PattenSebastian GrosickiHelen McCarthyFritz Offner et al.

Fixed-duration epcoritamab in combination with bendamustine plus rituximab for first-line treatment of follicular lymphoma : initial results from Epcore NHL-2 Arm 3

Joshua BrodyLorenzo FalchiUmberto VitoloMarcel NijlandFritz OffnerSylvia SnauwaertPoliana PatahJennifer MarekChristopher MorehouseAndrew J. Steele et al.

Fixed-duration epcoritamab plus R-CHOP induces high complete response rates in patients with previously untreated diffuse large B-cell lymphoma with high-risk features : long-term results from the Epcore NHL-2 trial

Lorenzo FalchiFritz OffnerSven de VosJoshua BrodyRaul CordobaKim LintonSylvia SnauwaertMichael Roost ClausenToshihiko OkiAndrew J. Steele et al.

Glofitamab induces high response rates and durable remissions in patients (Pts) with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL), including those with a poor prognosis : subgroup results from a Phase I/II study

Tycel J. PhillipsMarek TrnenyCarmelo Carlo-StellaJan Maciej ZauchaTomasz WrobelFritz OffnerMichael J. DickinsonMonica TaniMichael CrumpNancy L. Bartlett et al.

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase 1/2 study

Tycel PhillipsCarmelo Carlo-StellaFranck MorschhauserEmmanuel BachyMichael CrumpMarek TrnenyNancy L. BartlettJan ZauchaTomasz WrobelFritz Offner et al.

Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase I/II study

Tycel Jovelle PhillipsCarmelo Carlo-StellaFranck MorschhauserEmmanuel BachyMichael CrumpMarek TrnenyNancy L. BartlettJan ZauchaTomasz WrobelFritz Offner et al.

Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) : results from a phase I/II study

Nancy L. BartlettMichael DickinsonMartin HutchingsCarmelo Carlo-StellaShang-Ju WuSirpa LeppaMarek TrnenyPaolo CorradiniFritz OffnerEstefania Mulvihill et al.

High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma

Willem DaneelsAlexander Van ParysLeander HuygheElke RoggeSteffi De RouckRuben ChristiaenLennart ZabeauSylvie TaveirneJo Van DorpeNiko Kley et al.

A1 Journal Article in EXPERIMENTAL HEMATOLOGY & ONCOLOGY

Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen-induced exhaustion

Stijn De MunterJuliane L. BuhlLaurenz De CockAlexander Van ParysWillem DaneelsEva PascalLucas DeseinsJoline IngelsGlenn GoetgelukHanne Jansen et al.

A1 Journal Article in CANCER IMMUNOLOGY RESEARCH

Outcomes by refractory status and prior therapies received in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) from the ECHELON-3 study

Uwe HahnNancy L. BartlettJeong-A KimKrimo BouabdallahNicholas ForwardTsai-Yun ChenVincent CamusMing-Chung WangPhilippe CarassouEnrico Derenzini et al.

Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell Non-Hodgkin lymphoma (LOTIS-7)

Emily C. AyersJulien DepausFritz OffnerMarie HuCraig OkadaAndrzej UrbanAndrew NiewiarowskiErica RaveMary LaughlinJuan Pablo Alderuccio

Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging

Thomas Van Den BergheBert VerberckmoesNicolas KintSteven WallaertNicolas De VosChloé AlgoetMaxim BehaegheJulie DutoitNadine Van RoyPhilip Vlummens et al.

A1 Journal Article in INSIGHTS INTO IMAGING

Predicting cytogenetic risk in newly-diagnosed multiple myeloma patients using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI and spinal diffusion-weighted imaging

Thomas Van Den BergheBert VerberckmoesNicolas KintSteven WallaertChloé AlgoetJulie DutoitAmélie DendoovenFritz OffnerKoenraad Verstraete

Predicting cytogenetic risk in newly-diagnosed multiple myeloma patients using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI and spinal diffusion-weighted imaging

Thomas Van Den BergheBert VerberckmoesNicolas KintSteven WallaertChloé AlgoetJulie DutoitAmélie DendoovenFritz OffnerKoenraad Verstraete

2023

Blood plasma and FFPE derived total RNA seq dataset from DLBCL and PMBCL patients

Philippe DecruyenaereJo VandesompeleFritz Offner

Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel : phase 2 Elara 3-year follow-up

Stephen J. SchusterNathan FowlerMichael DickinsonJoaquin Martinez-LopezArne KolstadJason ButlerMonalisa GhoshLeslie L. PopplewellJulio C. ChavezEmmanuel Bachy et al.

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells

Dorien ClarisseStefan PrekovicPhilip VlummensEleni StaessensKarlien Van WesemaelJonathan ThommisDaria FijalkowskaGuillaume AckeWilbert ZwartIlse M. Beck et al.

A1 Journal Article in CELLULAR AND MOLECULAR LIFE SCIENCES

Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses

Simon HarrisonCaroline Hasselbalch RileySalomon ManierSung-Soo YoonAntonio PintoTitouan CazaubielAnna GuidettiRakesh PopatCyrille TouzeauEnrique Ocio et al.

ELARA trial update : long-term clinical outcomes and correlative efficacy analyses of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (R/R FL)

Nathan FowlerMartin DreylingMichael DickinsonJoaquin Martinez-LopezArne KolstadJason ButlerMonalisa GhoshLeslie PopplewellJulio ChavezEmmanuel Bachy et al.

Englumafusp alfa (CD19-4-1BBL) and glofitamab combination in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL) : biomarker results from a phase I dose-escalation trial

Koorosh KorfiAilsa ChristiansenZhiwen JiangSabine WilsonSamuel TracyAnnika BlankSylvia HerterNatalie DimierBruno GomesPablo Umana et al.

Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia : results from the phase 1b/2 EPCORE CLL-1 trial expansion cohort

Arnon KaterHerbert EradatCarsten NiemannFritz OffnerChristian Bjorn PoulsenThor HoyerMar BellidoMazyar ShadmanToshihiko OkiAlexandra Kuznetsova et al.

Epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data

Lorenzo FalchiMichael Roost ClausenFritz OffnerSven de VosJoshua BrodyKim M. LintonSYLVIA SNAUWAERTRaul CordobaJun WuIrina Bykhovski et al.

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

Philippe DecruyenaereEdoardo GiuiliKimberly VerniersJasper AnckaertKatrien De GroveMalaïka Van der LindenDries DeerenJo Van DorpeFritz OffnerJo Vandesompele

A1 Journal Article in FRONTIERS IN ONCOLOGY

Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)

M. DreylingT. PhillipsM. DickinsonF. MorschhauserE. BachyM. CrumpM. TrnenyN. L. BartlettJ. ZauchaT. Wrobel et al.

Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed/ refractory mantle cell lymphoma

Tycel PhillipsMichael DickinsonFranck MorschhauserEmmanuel BachyMichael CrumpMarek TrnenyBartlett L. NancyJan ZauchaTomasz WrobelFritz Offner et al.

Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustion

Stijn De MunterJuliane BuhlLaurenz De CockAlexander Van ParysWillem DaneelsEva PascalLucas DeseinsJoline IngelsGlenn GoetgelukLore Billiet et al.

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial

Paul G. RichardsonThierry FaconChristopher P. VennerNizar J. BahlisFritz OffnerDarrell WhiteLionel KarlinLotfi BenboubkerEric VoogSung-Soo Yoon et al.

A2 Journal Article in EJHAEM

Long-term clinical outcomes and correlative efficacy analyses in patients (Pts) with relapsed/refractory (r/r) follicular lymphoma (FL) treated with tisagenlecleucel in the ELARA Trial

M. DreylingM. DickinsonJ. Martinez-LopezA. KolstadJ. ButlerM. GhoshL. PopplewellJ. C. ChavezE. BachyK. Kato et al.

Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated EPCORE NHL-2 data

Lorenzo FalchiMichael ClausenFritz OffnerSven De VosJoshua BrodyKim M. LintonSylvia SnauwaertRaul CordobaJun WuIrina Bykhovski et al.

Pan-cancer blood plasma cell-free RNA profiles reveal cancer type and patient-specific changes

Annelien MorlionPhilippe DecruyenaereKathleen SchoofsJasper AnckaertJustine NuytensEveline Vanden EyndeKimberly VerniersCeline EveraertFritz OffnerJo Van Dorpe et al.

Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls

Annelien MorlionPhilippe DecruyenaereKathleen SchoofsJasper AnckaertJustine NuytensEveline Vanden EyndeKimberly VerniersCeline EveraertFritz OffnerJo Van Dorpe et al.

Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma

Torben PlesnerSimon J. HarrisonHang QuachCindy LeeAdam BryantAnnette VangstedJane EstellMichel DelforgeFritz OffnerPatrick Twomey et al.

A2 Journal Article in CLINICAL HEMATOLOGY INTERNATIONAL

Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in Belgium after 4 years

Kirsten SaevelsSylvia SnauwaertGaeten VanstralenMarc AndreFritz OffnerAriane MaesMarjolein LahayeAnn Janssens

RNA extraction method impacts quality metrics and sequencing results in diffuse large B-cell lymphoma formalin-fixed paraffin-embedded tissue samples

Philippe DecruyenaereKimberly VerniersFranco Alexander Poma SotoJo Van DorpeFritz OffnerJo Vandesompele

RNA extraction method impacts quality metrics and sequencing results in formalin-fixed, paraffin-embedded tissue samples

Philippe DecruyenaereKimberly VerniersFranco Alexander Poma SotoJo Van DorpeFritz OffnerJo Vandesompele

A1 Journal Article in LABORATORY INVESTIGATION

Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

Simon HarrisonCaroline Hasselbalch RileySalomon ManierSung-Soo YoonAntonio PintoTitouan CazaubielAnna GuidettiRakesh PopatCyrille TouzeauEnrique Ocio et al.

Subcutaneous epcoritamab with R-CHOP in previously untreated high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma : updated results from EPCORE NHL-2

Lorenzo FalchiRoost Michael ClausenFritz OffnerSven de VosBrody D. JoshuaLinton M. KimSYLVIA SNAUWAERTRaul CordobaToshihiko OkiIrina Bykhovski et al.

Systemic mastocytosis with myeloid sarcoma and B-CLL : molecular and clonal heterogeneity in a rare case of SM-AHN

Philippe DecruyenaereDominiek MazureIne MoorsJo Van DorpeMalaïka Van der LindenBarbara DenysMattias HofmansFritz Offner

Systemic mastocytosis with myeloid sarcoma and B-CLL : molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature

Philippe DecruyenaereDominiek MazureIne MoorsJo Van DorpeMalaïka Van der LindenBarbara DenysMattias HofmansFritz Offner

A1 Journal Article in ACTA CLINICA BELGICA

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL : a multicentre, non-randomised, open-label phase 2 study

Radhakrishnan RamchandrenPeter JohnsonNilanjan GhoshJia RuanKirit M. ArdeshnaRoderick JohnsonGregor VerhoefDavid CunninghamSven de VosShireen Kassam et al.

A1 Journal Article in ECLINICALMEDICINE

2022

A unique phenotype of longitudinal extensive transverse myelitis in autoimmune lymphoproliferative syndrome

Cathérine DekeyserLeslie NaesensFritz OffnerCiel De VriendtAlexander SchauwvliegheTessa KerreGuy Laureys

A1 Journal Article in JOURNAL OF NEUROIMMUNOLOGY

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Arthur BobinMaeva KyhengStephanie GuidezCecile Gruchet-MerouzeValentine RichezAlain DuhamelLionel KarlinBrigitte KolbMourad TiabCarla Araujo et al.

A1 Journal Article in LEUKEMIA

CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell engaging bispecific antibody glofitamab in relapsed or refractory B-cell Non-Hodgkin lymphoma

Martin HutchingsCarmelo Carlo-StellaGiuseppe GrittiFrancesc BoschFranck MorschhauserWilliam TownsendFritz OffnerHarriet S. WalterHerve GhesquieresRoch Houot et al.

CD8 presence and dynamics in glofitamab-treated patients with relapsed/refractory B-cell Non-Hodgkin lymphoma using the CD8-specific PET tracer Zr-89-crefmirlimab berdoxam

Martin HutchingsAnnika LoftWendy OsborneGeorge PetridesFritz OffnerCiel De VriendtGiuseppe GrittiRoberto BoniWilliam TownsendIrfan Kayani et al.

Combining Ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia : final analysis of the phase I/II HOVON124/ECWM-R2 study

Marie Jose KerstenKarima AmaadorMonique C. MinnemaJosephine M. I. VosKazem NasserinejadMarcel KapEfstathios KastritisMaria GavriatopoulouWillem KraanMartine E. D. Chamuleau et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Comparison of the effectiveness and safety of the oral selective inhibitor of nuclear export, selinexor, in diffuse large B cell lymphoma subtypes

Rene-Olivier CasasnovasGeorge FollowsJosee M. ZijlstraJoost S. P. VermaatNagesh KalakondaSylvain ChoquetEric Van den NesteBrian HillCatherine ThieblemontFederica Cavallo et al.

A1 Journal Article in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma

Nicolas LeupinPier Luigi ZinzaniFranck MorschhauserStephane DalleMarie MaerevoetJean-Marie MichotVincent RibragFritz OffnerMarie Beylot-BarryHelene Moins-Teisserenc et al.

A1 Journal Article in CANCER

Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the SADAL study

Michael SchusterJosee ZijlstraRene-Olivier CasasnovasJoost S. P. VermaatNagesh KalakondaAndre GoySylvain ChoquetEric Van Den NesteBrian HillCatherine Thieblemont et al.

A1 Journal Article in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Effectiveness and safety of ibrutinib for chronic lymphocytic leukemia in routine clinical practice : 3-year follow-up of the Belgian Ibrutinib Real-World Data (BiRD) study

Ann JanssensZwi N. BernemanFritz OffnerSylvia SnauwaertPhilippe MineurGaetan VanstraelenStef MeersIsabelle SpoormansDominique BronIsabelle Vande Broek et al.

A2 Journal Article in CLINICAL HEMATOLOGY INTERNATIONAL

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) : phase 1/2 data update

Lorenzo FalchiFritz OffnerDavid BeladaJoshua BrodyKim M. LintonYasmin KarimiRaul CordobaSylvia SnauwaertAqeel AbbasLiwei Wang et al.

Five-year results and overall survival update from the phase 3 randomized study AUGMENT : lenalidomide plus rituximab (R-2) vs rituximab plus placebo in patients with relapsed/refractory indolent Non-Hodgkin lymphoma

John P. LeonardMarek TrnenyFritz OffnerJiri MayerHuilai ZhangGrzegorz S. NowakowskiPhillip ScheinbergArgyrios GkasiamisJoanna Mikita-GeoffroyEverton Rowe et al.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

Michael J. DickinsonCarmelo Carlo-StellaFranck MorschhauserEmmanuel BachyPaolo CorradiniGloria IacoboniCyrus KhanTomasz WrobelFritz OffnerShang-Ju Wu et al.

A1 Journal Article in NEW ENGLAND JOURNAL OF MEDICINE

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior lines of therapy : key results of the phase-II expansion

M. HutchingsM. DickinsonC. Carlo-StellaF. MorschhauserE. BachyP. CorradiniG. IacoboniC. KhanT. WrobelFritz Offner et al.

Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results

Michael DickinsonCarmelo Carlo-StellaFranck MorschhauserEmmanuel BachyPaolo CorradiniGloria IacoboniCyrus KhanTomasz WrobelFritz OffnerMarek Trneny et al.

Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma

Tycel J. PhillipsMichael DickinsonFranck MorschhauserEmmanuel BachyMichael CrumpMarek TrnenyNancy L. BartlettJan ZauchaTomasz WrobelFritz Offner et al.

Identifying patients with chronic lymphocytic leukemia without need of treatment : end of endless watch and wait?

Christian BrieghelVeerle GalleRudi AgiusCaspar Da Cunha-BangMichael A. AndersenPhilip VlummensMattias MattssonRichard RosenquistKarin E. SmedbyCarmen D. Herling et al.

A1 Journal Article in EUROPEAN JOURNAL OF HAEMATOLOGY

Inhibition of the protein arginine methyltransferase PRMT5 in high-risk multiple myeloma as a novel treatment approach

Philip VlummensStefaan VerhulstKim De VeirmanAnke MaesEline MenuJerome MoreauxHugues De BoussacNicolas RobertElke De BruyneDirk Hose et al.

A1 Journal Article in FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY

Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed/refractory multiple myeloma (RRMM) : biomarker results from a phase I study

Iryna DekhtiarenkoIva LeliosJan AttigNassim SleimanDomenico LazzaroEmilie SchindlerJan EckmannPablo UmanaWolfgang JacobMeike Schneider et al.

Isolated amyloidosis of the gastro-intestinal tract

S. SmeetsF. DedeurwaerdereE. ThomaereB. HouthoofdL. D'HulstP. WilmesFritz OffnerS. De Coninck

U Journal Article in ACTA GASTRO-ENTEROLOGICA BELGICA

Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the ELARA trial

Martin DreylingMichael DickinsonJoaquin Martinez LopezArne KolstadJason P. ButlerMonalisa GhoshLeslie L. PopplewellJulio ChavezEmmanuel BachyKoji Kato et al.

Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from Ibrutinib treatment up to 8 years : a plain language summary

Paul M. BarrCarolyn OwenTadeusz RobakAlessandra TedeschiOsnat BaireyJan A. BurgerPeter HillmenClaire DeardenSebastian GrosickiHelen McCarthy et al.

Editorial material

Nucleic acid biomarkers in Waldenstrom Macroglobulinemia and IgM-MGUS : current insights and clinical relevance

Daniela DrandiPhilippe DecruyenaereMartina FerranteFritz OffnerJo VandesompeleSimone Ferrero

A1 Journal Article in DIAGNOSTICS

Prolonged remissions after nivolumab plus gemcitabine/oxaliplatin in relapsed/refractory T-cell lymphoma

Roch HouotViola PoeschelBettina AltmannStephanie AngelLorenz ThurnerThomas IllmerMarc AndreMartin DreylingHerve MaisonneuveHerve Tilly et al.

A1 Journal Article in HEMASPHERE

Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data : a Belgian population-based study

Willem DaneelsMichael RosskampGilles MacqEstabraq Ismael SaadoonAnke De GeyndtFritz OffnerHélène A. Poirel

A1 Journal Article in FRONTIERS IN ONCOLOGY

RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study

Carmelo Carlo-StellaRita MazzaSalomon ManierThierry FaconSung-Soo YoonYoungil KohSimon J. HarrisonJeremy ErAntonio PintoFrancesco Volzone et al.

Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis : a standardized approach with underappreciated potential

Lennart RamanMalaïka Van der LindenCiel De VriendtBliede Van den BroeckKristoff MuylleDries DeerenFranceska DedeurwaerdereSofie VerbekeAmélie DendoovenKatrien De Grove et al.

A1 Journal Article in HAEMATOLOGICA

Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential

Lennart RamanMalaïka Van Der LindenCiel De VriendtBliede Van den BroeckKristoff MuylleDries DeerenFranceska DedeurwaerdereSofie VerbekeAmélie DendoovenKatrien De Grove et al.

U Journal Article in Haematologica

Subcutaneous epcoritamab in combination with rituximab plus lenalidomide (R-2) for first-line treatment of follicular lymphoma : initial results from phase 1/2 trial

Lorenzo FalchiLori A. LeslieDavid BeladaKaterina KopeckovaFritz OffnerJoshua BrodyMiguel CanalesAlejandro Martin Garcia-SanchoMarcel NijlandP-O Andersson et al.

Subcutaneous epcoritamab plus R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT) : preliminary phase 1/2 results

Pau AbrisquetaLorenzo FalchiTycel Jovelle PhillipsSven De VosMarcel NijlandFritz OffnerIrina BykhovskiJun WuLiwei WangAli Rana et al.

The association between patient characteristics and the efficacy and safety of selinexor in diffuse large B-cell lymphoma in the SADAL study

Josee M. ZijlstraGeorge FollowsRene-Olivier CasasnovasJoost S. P. VermaatNagesh KalakondaSylvain ChoquetBrian HillCatherine ThieblemontFederica CavalloFatima De la Cruz et al.

A1 Journal Article in CANCERS

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma : the phase 2 ELARA trial

Nathan Hale FowlerMichael DickinsonMartin DreylingJoaquin Martinez-LopezArne KolstadJason ButlerMonalisa GhoshLeslie PopplewellJulio C. ChavezEmmanuel Bachy et al.

A1 Journal Article in NATURE MEDICINE

Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Paul M. BarrCarolyn OwenTadeusz RobakAlessandra TedeschiOsnat BaireyJan A. BurgerPeter HillmenSteve E. CoutreClaire DeardenSebastian Grosicki et al.

A1 Journal Article in BLOOD ADVANCES

2021

Avelumab in combination regimens for relapsed/refractory DLBCL : results from the phase Ib JAVELIN DLBCL study

Eliza A. HawkesTycel PhillipsLihua Elizabeth BuddeArmando SantoroNakhle S. SabaFernando RoncolatoGareth P. GregoryGregor VerhoefFritz OffnerCristina Quero et al.

A1 Journal Article in TARGETED ONCOLOGY

Circulating RNA biomarkers in diffuse large B-cell lymphoma : a systematic review

Philippe DecruyenaereFritz OffnerJo Vandesompele

A1 Journal Article in EXPERIMENTAL HEMATOLOGY & ONCOLOGY

Covalent cysteine targeting of Bruton's tyrosine kinase (BTK) family by withaferin-A reduces survival of glucocorticoid-resistant multiple myeloma MM1 cells

Emilie LogieChandra S. ChirumamillaClaudina Perez-NovoPriyanka ShawKen DeclerckAjay PalaganiSavithri RangarajanBart CuypersNicolas De NeuterFazil Mobashar Hussain Urf Turabe et al.

A1 Journal Article in CANCERS

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice

Tim PietersSara T'SasStijn VanheeAndré Pedro Pinto De AlmeidaYasmine DriegeJuliette RoelsWouter Van LoockeWillem DaneelsMathijs BaensArnaud Marchand et al.

A1 Journal Article in JOURNAL OF EXPERIMENTAL MEDICINE

Glofitamab step-up dosing (SUD) : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (Pts)

Carmelo Carlo-StellaCyrus KhanMartin HutchingsFritz OffnerFranck MorschhauserEmmanuel BachyMichael CrumpAnna SuredaGloria IacoboniCorinne Haioun et al.

Glofitamab step-up dosing : updated efficacy data show high complete response rates in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (PTS)

C. Carlo-StellaM. HutchingsFritz OffnerF. MorschhauserE. BachyM. CrumpA. SuredaG. IacoboniC. HaiounD. Perez-Callejo et al.

Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial

Martin HutchingsFranck MorschhauserGloria IacoboniCarmelo Carlo-StellaFritz OffnerAnna SuredaGilles SallesJoaquin Martinez-LopezMichael CrumpDenise N. Thomas et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

Jatin ShahSharon ShachamMichael KauffmanPatrick DanieleDimitrios TomarasGabriel TremblayRene-Olivier CasasnovasMarie MaerevoetJosee ZijlstraGeorge Follows et al.

A1 Journal Article in FUTURE ONCOLOGY

Long-term follow-up, up to 7 years, in the RESONATE-2 study of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL)

Jan BurgerPaul BarrCarolyn OwenTadeusz RobakAlessandra TedeschiOsnat BaireyPeter HillmenSteve CoutreStephen DevereuxSebastian Grosicki et al.

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

Philippe MoreauCyrille HulinAurore PerrotBertrand ArnulfKarim BelhadjLotfi BenboubkerMarie C. BeneSonja ZweegmanHelene CaillonDenis Caillot et al.

A1 Journal Article in LANCET ONCOLOGY

Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the NIVEAU trial

G. HeldV PoeschelB. AltmannT. IllmerM. AndreM. DreylingH. MaisonneuveH. TillyS. MayerR. -O Casasnovas et al.

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry FaconChristopher P. VennerNizar J. BahlisFritz OffnerDarrell J. WhiteLionel KarlinLotfi BenboubkerSophie RigaudeauPhilippe RodonEric Voog et al.

A1 Journal Article in BLOOD

Real world application of R‐chop for diffuse large B‐cell lymphoma (DLBCL) in Belgium and its impact on survival

Willem DaneelsM. RosskampG. MacqEstabraq Ismael SaadoonA. DegeyndtFritz OffnerH. Antoine‐Poirel

Real world population-based study of treatment-modalities of diffuse large B-cell lymphoma in Belgium : focus on the older population

Willem DaneelsMichael RosskampGilles MacqEstabraq Ismael SaadoonAnke De GeyndtFritz OffnerA. Poirel Hélène

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

Cyrille HulinFritz OffnerPhilippe MoreauMurielle RousselKarim BelhadjLotfi BenboubkerDenis CaillotThierry FaconLaurent GarderetFrederique Kuhnowski et al.

A1 Journal Article in HAEMATOLOGICA

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Marie MaerevoetJosee M. ZijlstraGeorge FollowsRene-Olivier CasasnovasJ. S. P. VermaatNagesh KalakondaAndre GoySylvain ChoquetEric Van den NesteBrian Hill et al.

A1 Journal Article in JOURNAL OF HEMATOLOGY & ONCOLOGY

Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Paul M. BarrCarolyn OwenTadeusz RobakAlessandra TedeschiOsnat BaireyJan Andreas BurgerPeter HillmenSteve E. CoutreStephen DevereuxSebastian Grosicki et al.

When hematochezia becomes a red herring

Sander SmeetsF. DedeurwaerdereE. ThomaereB. HouthoofdL. D'HulstP. WilmesFritz OffnerS. De Coninck

Editorial material

2020

A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil : final analysis of the Complement 1 phase 3 trial

Fritz OffnerTadeusz RobakAnn JanssensK. Govind BabuJanusz KloczkoSebastian GrosickiJiri MayerPanagiotis PanagiotidisAnna SchuhAndrew Pettitt et al.

A1 Journal Article in BRITISH JOURNAL OF HAEMATOLOGY

Effect of age on the efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the sadal pivotal study

Michael W. SchusterMiguel A. CanalesJason WestinJosee M. ZijlstraGeorge A. FollowsReem KarmaliNagesh KalakondaAndre H. GoyRene-Olivier CasasnovasJoost Vermaat et al.

Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma : interim analysis of the phase 2 ELARA trial

Nathan H. FowlerMichael DickinsonMartin DreylingJoaquin Martinez-LopezArne KolstadJason P. ButlerMonalisa GhoshLeslie L. PopplewellJulio C. ChavezEmmanuel Bachy et al.

Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) : durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation

M. HutchingsF. MorschhauserG. IacoboniC. Carlo-StellaFritz OffnerA. SuredaG. SallesJ. Martinez-LopezM. CrumpL. Lundberg et al.

Health utility in relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) patients : results of a phase II trial with oral selinexor

R. O. CasasnovasP. DanieleG. TremblayM. MaerevoetJ. ZijlstraG. FollowsJ. S. P. VermaatN. KalakondaA. H. GoyS. Choquet et al.

Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age : results with 5 years of follow-up for the RESONATE-2 study

Alessandra TedeschiJan A. BurgerPaul BarrTadeusz RobakCarolyn OwenPaolo GhiaOsnat BaireyPeter HillmenSteven CoutreStephen Devereux et al.

Ixazomib plus lenalidomide-dexamethasone (IRd) vs. placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant : the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial

Thierry FaconChristopher P. VennerNizar J. BahlisMichel AttalFritz OffnerDarrell J. WhiteLionel KarlinLotfi BenboubkerSophie RigaudeauPhilippe Rodon et al.

Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies

Dorien ClarisseFritz OffnerKarolien De Bosscher

A1 Journal Article in BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study

Jan A. BurgerPaul M. BarrTadeusz RobakCarolyn OwenPaolo GhiaAlessandra TedeschiOsnat BaireyPeter HillmenSteven E. CoutreStephen Devereux et al.

A1 Journal Article in LEUKEMIA

Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the niveau trial

Roch HouotViola PoeschelBettina AltmannThomas IllmerMarc AndreMartin DreylingHerve MaisonneuveHerve TillyStephanie MayerRene-Olivier Casasnovas et al.

Phase 1 study of CD19 targeted 4-1BBL costimulatory agonist to enhance T cell (glofitamab combination) or NK cell effector function (obinutuzumab combination) in relapsed/refractory B cell lymphoma

Martin HutchingsFritz OffnerFrancesc BoschGiuseppe GrittiCarmelo Carlo-StellaHarriet WalterWilliam TownsendFranck MorschhauserGuillaume CartronHerve Ghesquieres et al.

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia : results from the pivotal phase III study COMPLEMENT1

Eugen TauschPhilipp BeckRichard F. SchlenkBilly M. C. JebarajAnna DolnikDeyan Y. YosifovPeter HillmenFritz OffnerAnn JanssensK. Govind Babu et al.

A1 Journal Article in HAEMATOLOGICA

Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival

Willem DaneelsMichael RosskampGilles MacqEstabraq Ismael SaadoonTim De GeyndtFritz OffnerHélène Antoine-Poirel

Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival

Willem DaneelsMichael RosskampGilles MacqEstabraq Ismael SaadoonAnke De GeyndtFritz OffnerHélène Antoine-Poirel

Selinexor efficacy and safety are independent of renal function in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis from the pivotal phase 2b sadal study

Michael W. SchusterMiguel A. CanalesJason WestinJosee M. ZijlstraGeorge A. FollowsReem KarmaliNagesh KalakondaAndre H. GoyRene-Olivier CasasnovasJoost Vermaat et al.

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh KalakondaMarie MaerevoetFederica CavalloGeorge FollowsAndre GoyJoost S. P. VermaatOlivier CasasnovasNada HamadJosee M. ZijlstraSameer Bakhshi et al.

A1 Journal Article in LANCET HAEMATOLOGY

Shallow whole-genome sequencing of cell-free DNA for B-cell lymphoma diagnosis and disease monitoring : a standardized approach with underappreciated potential

Malaïka Van der LindenLennart RamanCiel De VriendtBliede Van den BroeckKristoff MuylleDries DeerenKathleen ClaesBjörn MentenFritz OffnerJo Van Dorpe

Shallow whole-genome sequencing of cell-free DNA for B-cell lymphoma diagnosis and disease monitoring: a standardized approach with underappreciated potential

Malaïka Van der LindenLennart RamanCiel De VriendtBliede Van den BroeckKristoff MuylleDries DeerenKathleen ClaesBjörn MentenFritz OffnerJo Van Dorpe

2019

A phase 2b study of selinexor in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Nagesh KalakondaFederica CavalloGeorge FollowsAndre GoyJoost S. P. VermaatOlivier CasasnovasOrly LaveeMarie MaerevoetJosee ZijlstraSameer Bakhshi et al.

AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

John P LeonardMarek TrnenyKoji IzutsuNathan H FowlerXiaonan HongJun ZhuHuilai ZhangFritz OffnerAdriana ScheligaGrzegorz S Nowakowski et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03) : a phase I trial

Xavier LeleuGuillemette FouquetValentine RichezStephanie GuidezAlain DuhamelFrancois MachuronLionel KarlinBrigitte KolbMourad TiabCarla Araujo et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

Characterization of duvelisib in patients with refractory marginal zone lymphoma : data from the phase 2 DYNAMO trial

Eric JacobsenJuraj UraKirit ArdeshnaMohamad CherryFritz OffnerJiri MayerFontanet BijouMonica TaniGerardo MusuracaMichele Merli et al.

Characterization of duvelisib in patients with refractory marginal zone lymphoma : data from the phase 2 DYNAMO trial

Eric JacobsenJuraj DurasKirit ArdeshnaMohamad CherryFritz OffnerJiri MayerFontanet BijouMonica TaniGerardo MusuracaMichele Merli et al.

Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin lymphoma : preliminary results from a phase Ib trial

Franck MorschhauserCarmelo Carlo-StellaFritz OffnerGilles A. SallesMartin HutchingsGloria IacoboniAnna SuredaMichael CrumpJoaquin Martinez-LopezDenise Thomas et al.

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Nicole LamannaMarco MontiloArpad IllesGabriel EtienneJulio DelgadoBryone J KussConstantine S TamFritz OffnerFrancesc BoschMatthew S Davids et al.

Effect of dose modifications on response to duvelisib in patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO trial

Ian FlinnMarco MontilloArpad IllesGabriel EtienneJulio DelgadoBryone KussConstantine TamFritz OffnerFrancesc BoschMatthew Davids et al.

Effect of prior therapy on the efficacy and safety of oral Selinexor in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the SADAL study

Federica CavalloGeorge A. FollowsAndre GoyJoost VermaatRene-Olivier CasasnovasOrly LaveeMarie MaerevoetJosee M. ZijlstraSameer BakhshiReda Bouabdallah et al.

Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)

John G. GribbenKoji IzutsuNathan Hale FowlerXiaonan HongHuilai ZhangFritz OffnerAdriana A. S. ScheligaGrzegorz S. NowakowskiAntonio PintoFrancesca Re et al.

Exploring the potential of shallow whole-genome sequencing for diagnosis and disease monitoring of lymphoma in liquid biopsy

Lennart RamanMalaïka Van der LindenCiel De VriendtBliede Van den BroeckKristoff MuylleDries DeerenBjörn MentenFritz OffnerJo Van Dorpe

Five-year follow-up after ibrutinib therapy for first-line treatment of chronic lymphocytic leukemia

Jan BurgerAlessandra TedeschiPaul M. BarrTadeusz RobakCarolyn OwenPaolo GhiaOsnat BaireyPeter HillmenSteven E. CoutreStephen Devereux et al.

Implication of inherited genetic variants associated with follicular lymphoma susceptibility in the prognosis of patients treated by immunochemotherapy in PRIMA study

Herve GhesquieresYouenn DrouetSarah HuetGuillaume CartronMarie-Helene DelfauFritz OffnerPauline BriceLuc XerriReda BouabdallahGilles A. Salles

Ixazomib, Rituximab and Dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom's macroblobulinemia : results of the prospective phase I/II hovon 124/Ecwm-R2 trial

Marie Jose KerstenMonique C. MinnemaJosephine M. VosKazem NasserinejadMarcel KapEftathios KastritisMaria GavriatopoulouMartine E. D. ChamuleauDries DeerenLidwine Winnifred et al.

Lenalidomide/rituximab (R2) versus rituximab/placebo efficacy by POD24 status and time to next treatment in patients with relapsed/refractory indolent NHL (AUGMENT)

A PintoJ GribbenM TrnenyK IzutsuNH FowlerX HongH ZhangFritz OffnerA ScheligaG Nowakowski et al.

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.

Fritz OffnerTadeusz RobakAnn JanssensGovind Babu KanakasettyJanusz KloczkoSebastian GrosickiJiri MayerPanagiotis PanagiotidisAnna SchuhAndrew Pettitt et al.

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia : final analysis of the PROLONG study

Marinus van OersLukas SmolejMario PetriniFritz OffnerSebastian GrosickiMark-David LevinJaclyn DavisHiya BanerjeeTommaso StefanelliPetra Hoever et al.

A1 Journal Article in BLOOD CANCER JOURNAL

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

Meletios A. DimopoulosFrancesca GayFredrik SchjesvoldMeral BeksacRoman HajekKatja Christina WeiselHartmut GoldschmidtVladimir MaisnarPhilippe MoreauChang Ki Min et al.

A1 Journal Article in LANCET

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Stephan StilgenbauerTherese Aurran SchleinitzBarbara EichhorstFabian LangFritz OffnerJean-Francois RossiWilfried SchroyensEric Van den NesteLoic YsebaertUte von Wangenheim et al.

A1 Journal Article in LEUKEMIA

Phase 2 results of the iR(2) Regimen (Ibrutinib, Lenalidomide, and Rituximab) in patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Radhakrishnan RamchandrenPeter JohnsonNilanjan GhoshJia RuanKirit M. ArdeshnaRoderick JohnsonGregor VerhoefDavid CunninghamSven de VosShireen Kassam et al.

Phase III randomized AUGMENT study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with relapsed/refractory indolent non-hodgkin lymphoma

J. GribbenM. TrnenyK. IzutsuN. H. FowlerX. HongJ. ZhuH. ZhangFritz OffnerA. ScheligaG. Nowakowski et al.

Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival

Willem DaneelsMichael RosskampGilles MacqEstabraq Ismael SaadoonAnke De GeyndtFritz OffnerHelene A Poirel

Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study

Emmanuel BachyJohn F. SeymourPierre FeugierFritz OffnerArmando Lopez-GuillermoDavid BeladaLuc XerriJohn V. CatalanoPauline BriceFrancois Lemonnier et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

The anaphase-promoting complex/cyclosome : a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

Anke MaesKen MaesHendrik De RaeveEva De SmedtPhilip VlummensVanessa SzablewskiJulie DevinSylvia FaictKim De VeirmanEline Menu et al.

A1 Journal Article in BRITISH JOURNAL OF CANCER

The use of murine models for studying mechanistic insights of genomic instability in multiple myeloma

Philip VlummensKim De VeirmanEline MenuElke De BruyneFritz OffnerKarin VanderkerkenKen Maes

A1 Journal Article in FRONTIERS IN GENETICS

2018

A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma : a retrospective training and validation analysis in three international cohorts

Sarah HuetBruno TessonJean-Philippe JaisAndrew L FeldmanLaura MagnanoEmilie ThomasAlexandra Traverse-GlehenBenoit AlbaudMarjorie CarrereLuc Xerri et al.

A1 Journal Article in LANCET ONCOLOGY

Argx-110 for treatment of CD70-positive advanced cutaneous T-cell lymphoma in a phase 1/2 clinical trial

Martine BagotMarie MaerevoetPier Luigi ZinzaniFritz OffnerFranck MorschhauserJean-Marie MichotVincent RibragMaxime BattistellaHelene MoinsAngelica Calleri et al.

AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma

John P LeonardMarek TrnenyKoji IzutsuNathan H FowlerXiaonan HongJun ZhuHuilai ZhangFritz OffnerAdriana ScheligaGrzegorz S Nowakowski et al.

CD20-Tcb (RG6026), a novel '' 2:1 '' format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma : preliminary results from a phase I first in human trial

Martin HutchingsGloria IacoboniFranck MorschhauserFritz OffnerAnna SuredaGilles Andre SallesCarmelo Carlo-StellaJoaquin Martinez LopezDenise ThomasPeter N Morcos et al.

Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma : an analysis of two LYSA studies

Aurélie Cabannes-HamyFrederic PeyradeFabrice JardinJean-François EmileVincent DelwailNicolas MounierCorinne HaiounAurore PerrotOlivier FitoussiDiane Lara et al.

A1 Journal Article in CANCER MEDICINE

Characterization of the long-term efficacy and safety of duvelisib monotherapy in patients with relapsed/refractory CLL/SLL on treatment for > 2 years across 4 clinical studies

Ian W FlinnMarco MontilloZsolt NagyZoltan GasztonyiMatthew S DavidsKlaus GeisslerJose J Rifon RocaLeanne BerkhanFritz OffnerNgocDiep Le et al.

Effect of combining glucocorticoids with Compound A on glucocorticoid receptor responsiveness in lymphoid malignancies

Dorien ClarisseKarlien Van WesemaelJan TavernierFritz OffnerIlse BeckKarolien De Bosscher

A1 Journal Article in PLOS ONE

Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

S RuleW JurczakM JerkemanC RusconiM TrnenyFritz OffnerD CaballeroC JoaoM Witzens-HarigG Hess et al.

A1 Journal Article in LEUKEMIA

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Robert J KreitmanClaire DeardenPier Luigi ZinzaniJulio DelgadoLionel KarlinTadeusz RobakDouglas E GladstonePhilipp le CoutreSascha DietrichMirjana Gotic et al.

A1 Journal Article in LEUKEMIA

Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies

Martin DomFritz OffnerWim Vanden BergheXaveer Van Ostade

A1 Journal Article in JOURNAL OF PROTEOMICS

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : extended phase 3 results from RESONATE-2

Paul M BarrTadeusz RobakCarolyn OwenAlessandra TedeschiOsnat BaireyNancy L BartlettJan A BurgerPeter HillmenSteven CoutreStephen Devereux et al.

A1 Journal Article in HAEMATOLOGICA

The iR(2) regimen (ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphoma

Radhakrishnan RamchandrenPeter JohnsonNilanjan GhoshJia RuanKirit M ArdeshnaRoderick JohnsonGregor VerhoefDavid CunninghamSven de VosShireen Kassam et al.

The light chain IgLV3-21 defines a new poor prognostic subgroup in chronic lymphocytic leukemia : results of a multicenter study

Basile StamatopoulosThomas SmithEmerence CrompotKarlien PietersRuth CliffordMarek MrazPauline RobbeAdam BurnsAdele TimbsDavid Bruce et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

The phase 3 DUO trial : duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W FlinnPeter HillmenMarco MontilloZsolt NagyArpad IllesGabriel EtienneJulio DelgadoBryone J KussConstantine S TamZoltan Gasztonyi et al.

A1 Journal Article in BLOOD

2017

Coregulator profiling of the glucocorticoid receptor in lymphoid malignancies

Dorien ClarisseJonathan ThommisKarlien Van WesemaelRene HoutmanDariusz RatmanJan TavernierFritz OffnerIlse BeckKarolien De Bosscher

A1 Journal Article in ONCOTARGET

Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Robert W ChenStephen Maxted AnselPier Luigi ZinzaniJeffrey L VacircaArmando Lopez-GuillermoMartin HutchingsWojciech JurczakGeorg HessSteven Le GouillFritz Offner et al.

Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies

Philippe AftimosChristian RolfoSylvie RotteyFritz OffnerDominique BronMarie MaerevoetJean-Charles SoriaMahan MoshirTorsten DreierLuc Van Rompaey et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia : results of a phase II study

Vincent RibragWon Seog KimReda BouabdallahSoon Thye LimBertrand CoiffierArpad IllesBernard LemieuxMartin JS DyerFritz OffnerZakia Felloussi et al.

A1 Journal Article in HAEMATOLOGICA

The impact of the updated IMWG diagnostic criteria in a real-life SMM cohort : a single center experience

Philip VlummensFritz Offner

2016

A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL

Ian W FlinnPanayiotis PanayiotidisBoris AfanasyevAnn JanssensSebastian GrosickiWojciech HomendaLukas SmolejKazimierz KuliczkowskiMichael DoubekNatalia Domnikova et al.

A1 Journal Article in AMERICAN JOURNAL OF HEMATOLOGY

A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody (TM) ARGX-110

JM MichotM MaerevoetP AftimosSylvie RotteyC RolfoFritz OffnerL Van RompaeyM MoshirH de HaardK Silence et al.

A phase I study in T cell lymphoma patients treated with anti-CD70 simple antibody T ARGX-110

JM MichotK SilenceM MaerevoetP AftimosS RotteyC RolfoFritz OffnerL Van RompaeyM MoshirH de Haard et al.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study

Meletios A DimopoulosPhilippe MoreauAntonio PalumboDouglas JoshuaLudek PourRoman HájekThierry FaconHeinz LudwigAlbert OriolHartmut Goldschmidt et al.

A1 Journal Article in LANCET ONCOLOGY

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

X LeleuG FouquetL KarlinB KolbM TiabC AraujoN MeulemanT de RevelP BourquardP Lenain et al.

Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110

Jean-Marie MichotMarie MaerevoetPhilippe Georges AftimosSylvie RotteyChristian Diego RolfoFritz OffnerLuc Van RompaeyMahan MoshirHans de HaardKaren Silence et al.

Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma

Julie DutoitEveline ClausFritz OffnerLucien NoensJoris DelangheKoenraad Verstraete

A1 Journal Article in EUROPEAN JOURNAL OF RADIOLOGY

Daratumumab, lenalidomide, and dexamethasone for multiple myeloma

MA DimopoulosA OriolH NahiJ San-MiguelNJ BahlisSZ UsmaniN RabinRZ OrlowskiM KomarnickiK Suzuki et al.

A1 Journal Article in NEW ENGLAND JOURNAL OF MEDICINE

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

Peter HillmenAnn JanssensK Govind BabuJanusz KloczkoSebastian GrosickiStephanie MansonAstrid McKeownIra GuptaChai-Ni ChangFritz Offner

A1 Journal Article in ACTA ONCOLOGICA

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

RS SilvaNL BartlettMS DilhuydyA AvigdorA MatoMA PavlovskyFritz Offner

A1 Journal Article in LANCET ONCOLOGY

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study

Martin DreylingWojciech JurczakMats JerkemanRodrigo Santucci SilvaChiara RusconiMarek TrnenyFritz OffnerDolores CaballeroCristina JoaoMathias Witzens-Harig et al.

A1 Journal Article in LANCET

Xavier LeleuGuillemette FouquetLionel KarlinBrigitte KolbMourad TiabCarla AraujoNathalie MeulemanJv MalfusonPascal BourquardPascal Lenain et al.

Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2 (TM)

P BarrT KippsT RobakA TedeschiC OwenP GhiaP HillmenFritz OffnerC MorenoC Zhou et al.

Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)

P GhiaA TedeschiPM BarrT RobakC OwenO BaireyP HillmenNL BartlettJ LiD Simpson et al.

International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))

J BurgerA TedeschiPM BarrT RobakC OwenP GhiaO BaireyP HillmenNL BartlettJ Li et al.

Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation

Ans RomboutSofie LustFritz OffnerEvelien NaessensBruno VerhasseltJan Philippé

A1 Journal Article in BRITISH JOURNAL OF CANCER

Plasma exposure to metabolites of monomethyl auristatin E (MMAE) in patients with relapsed/refractory Hodgkin lymphoma (HL) treated with brentuximab vedotin (BV)

A FasanmadeJ KinleyM BargfredeT WyantK VenkatakrishnanM QianM CwikM PatonSK BalaniI Purevjal et al.

Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma

Michael CrumpSirpa LeppäLuis FayadJe Jung LeeAlice Di RoccoMichinori OguraHans HagbergFrederick SchnellRobert RifkinAndreas Mackensen et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))

P HillmenA TedeschiPM BarrT RobakC OwenP GhiaO BaireyNL BartlettJ LiD Simpson et al.

Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial

Clémentine SarkozyMarek TrnenyLuc XerriNick WickhamPierre FeugierSirpa LeppäPauline BricePierre SoubeyranMaria Gomes Da SilvaChristiane Mounier et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments

Nora SundahlDorien ClarisseMarc BrackeFritz OffnerWim Vanden BergheIlse Beck

A2 Journal Article in ONCOSCIENCE

The mineralocorticoid receptor is involved in glucocorticoid resistance

Dorien ClarisseFritz OffnerKarolien De BosscherIlse Beck

Updated efficacy and safety from the phase 3 resonate-2 study : ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia

Paul BarrTadeusz RobakCarolyn J OwenAlessandra TedeschiOsnat BaireyNancy L BartlettJan BurgerPeter HillmenSteven CoutreStephen Devereux et al.

Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial

Cyrille HulinAndrew BelchChaim ShustikMaria Teresa PetrucciUlrich DührsenJin LuKevin SongPhilippe RodonBrigitte PégouriéLaurent Garderet et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma

David S SiegelMeletios DimopoulosSundar JagannathHartmut GoldschmidtSimon DurrantJonathan L KaufmanXavier LeleuArnon NaglerFritz OffnerThorsten Graef et al.

A1 Journal Article in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

2015

A phase I dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma

Markus HanssonPeter GimsingAshraf BadrosTitti Martinsson NiskanenHareth NahiFritz OffnerMorten SalomoElisabeth SonessonMorten Mau-SorensenYvonne Stenberg et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

Carfilzomib weekly plus melphalan and prednisone in newly diagnosed elderly multiple myeloma (IFM 2012-03)

Xavier LeleuLionel KarlinBrigitte KolbMourad TiabCarla AraujoNathalie MeulemanThierry De RevelPascal BourquardPascal LenainMurielle Roussel et al.

Chimeric antigen receptor transgenic, T cell receptor/CD3 negative monospecific T cells generated from cord blood CD34 positive cells

Yasmine Van CaeneghemGlenn GoetgelukKarin WeeningGreet VerstichelSarah BonteTom TaghonGeorges LeclercqFritz OffnerHinrich AbkenTessa Kerre et al.

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Peter HillmenTadeusz RobakAnn JanssensK Govind BabuJanusz KloczkoSebastian GrosickiMichael DoubekPanagiotis PanagiotidisEva KimbyAnna Schuh et al.

A1 Journal Article in LANCET

Combination of dexamethasone with the selective glucocorticoid receptor modulator, Compound A, does not enhance glucocorticoid responsiveness in lymphoid malignancies

Dorien ClarisseFritz OffnerMarc BrackeKarolien De BosscherIlse Beck

Effect of age on efficacy and safety outcomes in patients with newly diagnosed multiple myeloma receiving lenalidomide and low-dose dexamethasone (RD): the first trial

C HulinC ShustikA BelchMT PetrucciU DuehrsenJ LuK SongP RodonB PegourieL Garderet et al.

Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma : a retrospective analysis

Georg HessBertrand CoiffierMichael CrumpChristian GisselbrechtFritz OffnerJorge RomagueraLisa KangPadraig J. Moran

A2 Journal Article in EXPERIMENTAL HEMATOLOGY & ONCOLOGY

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Fritz OffnerOlga SamoilovaEvgenii OsmanovHyeon-Seok EomMax S ToppJoão RaposoViacheslav PavlovDeborah RicciShalini ChaturvediEugene Zhu et al.

A1 Journal Article in BLOOD

Health related quality of life and patient reported outcomes in patients receiving ofatumumab maintenance versus observation in the Prolong trial

M van OersK KuliczkowskiL SmolejM PetriniFritz OffnerS GrosickiMD LevinI GuptaJ PhillipsV Williams et al.

Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

JA BurgerA TedeschiPM BarrT RobakC OwenP GhiaO BaireyP HillmenNL BartlettJ Li et al.

A1 Journal Article in NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib vs temsirolimus: results from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma (MCL)

Simon RuleWojciech JurczakMats JerkemanRodrigo SantucciChiara RusconiMarek TrnenyFritz OffnerDolores CaballeroCristina JoaoMathias Witzens-Harig et al.

Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients

Ans RomboutBasile StamatopoulosLaurence LagneauxSofie LustFritz OffnerEvelien NaessensHanne VanderstraetenBruno VerhasseltJan Philippé

A1 Journal Article in PLOS ONE

Mimicking the tumor microenvironment of chronic lymphocytic leukemia in vitro critically depends on the type of B cell receptor stimulation

Ans RomboutSofie LustFritz OffnerEvelien NaessensBruno VerhasseltJan Philippé

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

Marinus HJ van OersKazimierz KuliczkowskiLukáš SmolejMario PetriniFritz OffnerSebastian GrosickiMark-David LevinIra GuptaJennifer PhillipsVanessa Williams et al.

A1 Journal Article in LANCET ONCOLOGY

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Gareth MorganAntonio PalumboSujith DhanasiriDawn LeeKatja WeiselThierry FaconMichel DelforgeAlbert OriolMohamed ZakiXin Yu et al.

A1 Journal Article in BRITISH JOURNAL OF HAEMATOLOGY

Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (PTS) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

S StilgenbauerT Aurran SchleinitzM HallekF LangFritz OffnerJ-F RossiW SchroyensE Van Den NesteL YsebaertP Blum et al.

Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20⁺ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study

Laurie H SehnAndre GoyFritz OffnerGiovanni MartinelliM Dolores CaballeroOle GadebergTara BaetzAndrew D ZelenetzGianluca GaidanoLuis E Fayad et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive CLL/SLL (RESONATE-2 (TM))

Alessandra TedeschiPaul M BarrTadeusz RobakCarolyn OwenPaolo GhiaOsnat BaireyPeter HillmenNancy L BartlettJianyong LiDavid Simpson et al.

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma

Myron S CzuczmanStephen KahanicAndres ForeroGlen DavisMihaela MunteanuEric Van den NesteFritz OffnerDominique BronDonald QuickNathan Fowler

A1 Journal Article in ANNALS OF HEMATOLOGY

Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma

Xiaolei ZhouJianmin WangJessica ZhangCatherine Copley-MerrimanYasuhiro TorigoeCarolina ReyesJohn F SeymourFritz OffnerMarek TrnenyGilles Andre Salles

A1 Journal Article in HEMATOLOGY

Telomere length and POT1 mutations in CLL: incidence, associations and clinical impact in the Complement 1 trial

BM Chelliah JebarajE TauschR SchlenkS KlessC GallerP HillmenFritz OffnerA JanssensT ZenzK Govindbabu et al.

2014

A phase I first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies

Ahmad AwadaChristian D RolfoSylvia RotteyLaure Ysebrant de LendonckWilfrled A SchroyensFritz OffnerKaren SilenceTorsten DreierMahan MoshirHans de Heard et al.

Abexinostat (S78454) a histone deacetylase inhibitor, in patients with refractory or relapsed Hodgkin's lymphoma, non-Hodgkin lymphoma and chronic lymphocytic leukaemia: preliminary phase II results

F Broussais-GuillaumotF MorschhauserL TerriouWS KimST LimM EgyedB CoiffierE BachyMJ DyerA Illes et al.

DUO: a phase 3 trial of the PL3K-delta,gamma inhibitor IPI-145 versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphorytic lymphoma

Ian FlinnUlrich JaegerFritz OffnerFlorence CymbalistaMichael HallekFederico Callgarls-CapploJulio DelgadoPeter HillmanMatthew Steven DavidsDavid Donald Wright et al.

Effect of age on efficacy and safety outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) receiving lenalidomide and low-dose dexamethasone (Rd): the first trial

Cyrille HulinThierry FaconChaim ShustikAndrew BelchMaria Teresa PetrucciUlrich DuehrsenJin LuKevin SongPhilippe RodonBrigitte Pegourie et al.

Gene mutations and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): results from the phase III study COMPLEMENT1 (OMB110911)

Eugen TauschChristina GallerRichard SchlenkPeter HillmenFritz OffnerAnn JanssensK GovindbabuJiri MayerSebastian GrosickiPanagiotis Panagiotidis et al.

Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis results

Marinus HJ van OersKazimierz KuliczkowskiLukas SmolejMario PetriniFritz OffnerSebastian GorsickiMark-David LevinIra GuptaJennifer PhillipsVanessa Williams et al.

Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone

G MorganJF San MiguelS DhanasiriD LeeA PalumboT FaconM ZakiX YuL SternasC Jacques et al.

Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis

Clémentine SarkozyLucile BaseggioPierre FeugierEvelyne Callet-BauchuLionel KarlinJohn F SeymourLaure LebrasAnne-Sophie MichalletFritz OffnerOlivier Dumas et al.

A1 Journal Article in BRITISH JOURNAL OF HAEMATOLOGY

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma

Michelle FanaleSarit AssoulineJohn KuruvillaPhilippe Solal-CélignyDae S HeoGregor VerhoefPaolo CorradiniJeremy S AbramsonFritz OffnerAndreas Engert et al.

A1 Journal Article in BRITISH JOURNAL OF HAEMATOLOGY

Polyfunctional tumor antigen-specific T cells generated in vitro from human CD34 positive precursor cells transduced to express T cell receptor alpha beta chains fused to CD28-CD3 zeta signaling cassette

Yasmine Van CaeneghemGlenn GoetgelukSYLVIA SNAUWAERTFritz OffnerReno DebetsTessa KerreBart Vandekerckhove

Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): overall survival (OS) results of MM-003 after adjustment for Res crossover

Gareth J MorganJesus San MiguelSujith DhanasiriDawn LeeAntonio PalumboThierry FaconMohamed H ZakiXin YuLars Axel SternasChristian Jacques et al.

Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line

Pieter GlibertLiesbeth VossaertKatleen Van SteendamStijn LambrechtFilip Van NieuwerburghFritz OffnerThomas KippsMaarten DhaenensDieter Deforce

A1 Journal Article in INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911)

E TauschC GallerRF SchlenkP HillmenFritz OffnerA JanssensK GovindbabuS GrosickiJ MayerP Panagiotidis et al.

2013

A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the prelude trial

Michael CrumpSirpa LeppaLuis E FayadJe-Jung LeeAlice Di RoccoMichinori OguraHans HagbergFrederick SchnellRobert M RifkinAndreas Mackensen et al.

Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Vincent RibragHervé TillyOlivier CasasnovasAndré BoslyReda BouabdallahRichard DelarueFrançois BoueDominique BronPierre FeugierCorinne Haioun et al.

A1 Journal Article in EUROPEAN JOURNAL OF CANCER

ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type

Jerina BoelensJean-Philippe JaisBarbara VanhoeckeIlse BeckHeleen Van MelckebekeJan PhilippéMarc BrackeFabrice JardinJosette BrièreKaren Leroy et al.

A1 Journal Article in LEUKEMIA RESEARCH

Glucocorticoids and tailored targeting of the unfolded protein response: searching for novel apoptosis inducing pathways in mature B-cell neoplasms

Jerina BoelensFritz Offner

In vitro apoptosis and clonal evolution in chronic lymphocytic leukemia : predictive value and possible influence on treatment

Ann JanssensFritz OffnerJan Philippé

NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-chi (O-Chl): results from the phase III study complement 1 (OMB110911)

Eugen TauschPhilipp BeckRichard F SchlenkSabrina KlessChristina GallerPeter HillmenFritz OffnerAnn JanssensK GovindbabuSebastian Grosicki et al.

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911)

Peter HillmenTadeusz RobakAnn JanssensK GovindbabuSebastian GrosickiJiri MayerPanagiotis PanagiotidisEva KimbyAnna SchuhThomas Boyd et al.

Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab

Bertrand CoiffierWeimin LiErin D HenitzJayaprakash D KarkeraReyna FavisDana GaffneyAlice ShapiroPanteli TheocharousYusri A ElsayedHelgi van de Velde et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

Luis FayadFritz OffnerMitchell R SmithGregor VerhoefPeter JohnsonJonathan L KaufmanAma RohatinerAnjali AdvaniJames ForanGeorg Hess et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Safety profile and clinical response to MEDI-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced B-cell malignancies

Andres Forero-TorresMehdi HamadaniMichelle A FanaleCeleste M BelloThomas J KippsFritz OffnerGregor VerhoefMassimo FedericoStephanie A GregoryAnne Sonet et al.

SAR245409 Monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study

Jennifer R BrownMehdi HamadaniJon ArnasonLionel KarlinJohn HayslipNina Wagner-JohnstonGuillaume CartronVincent RibragSophie de GuibertStephen Opat et al.

Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy

Gilles André SallesJohn Francis SeymourPierre FeugierFritz OffnerArmando Lopez-GuillermoDavid BeladaLuc XerriReda BouabdallahJohn CatalanoBrice Pauline et al.

2012

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR₃A and FCGR₂A polymorphisms

Hervé GhesquièresGuillaume CartronJohn Francis SeymourMarie-Hélène Delfau-LarueFritz OffnerPierre SoubeyranAurore PerrotPauline BriceRéda BouabdallahAnne Sonet et al.

A1 Journal Article in BLOOD

Early recognition of malignant lactic acidosis in clinical practice: report on 6 patients with haematological malignancies

EA De RaesDominique BenoitPieter DepuydtFritz OffnerJ NolletANNA VANTILBORGHEVA STEELLucien NoensJohan Decruyenaere

A1 Journal Article in ACTA CLINICA BELGICA

High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature

Ann JanssensNadine Van RoyBruce PoppeLucien NoensJan PhilippéFranki SpelemanFritz Offner

A1 Journal Article in EUROPEAN JOURNAL OF HAEMATOLOGY

2011

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Bertrand CoiffierEvgenii A OsmanovXiaoNan HongAdriana ScheligaJiri MayerFritz OffnerSimon RuleAdriana TeixeiraJan WalewskiSven de Vos et al.

A1 Journal Article in LANCET ONCOLOGY

Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy

M CrumpA ScheligaJ MayerFritz OffnerA TeixeiraK KuliczkowskiAM LiberatiCY OkadaDL EsseltineC Enny et al.

FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation

H GhesquieresJ SeymourFritz OffnerP FeugierP BriceC HaiounO CasasnovasJ CatalanoF JardinL Xerri et al.

Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma

Ioanna PapandreouNicholas C DenkoMichael OlsonHeleen Van MelckebekeSofie LustArvin TamDavid E Solow-CorderoDonna M BouleyFritz OffnerMaho Niwa et al.

A1 Journal Article in BLOOD

Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study

F MorschhauserJ SeymourP FeugierFritz OffnerA Lopez-GuillermoR BouabdallahL PedersenP BriceD BeladaL Xerri et al.

Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles

Mado VandewoestyneValerie PedeKathleen LambeinMaarten DhaenensFritz OffnerMarleen PraetJan PhilippéThomas J KippsDieter Deforce

A1 Journal Article in LEUKEMIA

Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy: results of a medical need program in Belgium

M DelforgeA MichielsC DoyenA KentosJ Van DroogenbroeckFritz OffnerG BriesH DemuynckMC VekemansN Meuleman et al.

A1 Journal Article in ACTA CLINICA BELGICA

Myeloma of the central nervous system: report of a single center case series

P VermeirenANNA VANTILBORGHFritz Offner

A1 Journal Article in ACTA CLINICA BELGICA

Neutrophil elastase is the 'histone H2A-specific protease'

Pieter GlibertMaarten DhaenensStijn LambrechtDirk ElewautFritz OffnerTJ KippsDieter Deforce

Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT : a single-centre experience

Pieter DepuydtTessa KerreLucien NoensJOKE NOLLETFritz OffnerJohan DecruyenaereDominique Benoit

A1 Journal Article in BONE MARROW TRANSPLANTATION

Pattern of infections observed during the maintenance phase in the PRIMA study

M BouteloupJ SeymourP FeugierFritz OffnerA Lopez-GuillermoR BouabdallahL PedersenP BriceD BeladaG Salles

Phase 2 studies of immunochemotherapy +/- bortezomib (VC) in newly diagnosed non-germinal center B-cell-like (GCB) DLBCL: rapid prospective identification of non-GCB patients (PTS)

Fritz OffnerB FerhanogluJA ReevesHS EomK DonerJ RaposoIW FlinnC SuhNM ChowhanS Prasad et al.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles SallesJohn Francis SeymourFritz OffnerArmando López-GuillermoDavid BeladaLuc XerriPierre FeugierRéda BouabdallahJohn Vincent CatalanoPauline Brice et al.

A1 Journal Article in LANCET

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (vol 377, pg 42, 2011)

Gilles SallesJohn Francis SeymourFritz Offner

Rituximab maintenance therapy for follicular lymphoma: reply

Gilles SallesJohn Francis SeymourFritz OffnerArmando Lopez-GuillermoLarissa MegeHervé Tilly

A1 Journal Article in LANCET

Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed follicular lymphoma (FL)

E KimbyA ScheligaJ MayerFritz OffnerA TeixeiraK KuliczkowskiAM LiberatiCY OkadaD EsseltineP Theocharous et al.

2010

Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma

G VerhoefN DangM SmithFritz OffnerP JohnsonA RohatinerJ KaufmanE GineB CoiffierM Czuczman et al.

Aspiration pneumonia : an underestimated cause of severe respiratory failure in patients with haematological malignancies and severe oral mucositis?

Nicolaas De NeveDominique BenoitPieter DepuydtFritz OffnerJOKE NOLLETLucien NoensJohan Decruyenaere

A1 Journal Article in ACTA CLINICA BELGICA

Characterization of the unfolded protein response by pharmacological agents in lymphoid malignancies

Sofie LustFritz OffnerMarc Bracke

Impact of organ dysfunction on mortality in ICU patients with hematologic malignancies

Dominique VandijckPieter DepuydtFritz OffnerJOKE NOLLETRenaat PelemanEVA STEELLucien NoensJohan DecruyenaereDominique Benoit

A1 Journal Article in INTENSIVE CARE MEDICINE

Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

G SallesJ CatalanoP FeugierFritz OffnerR BouabdallahD CaballeroP BriceLM PedersenC HaiounD Belada et al.

The flavonoid tangeretin activates the unfolded protein response and synergizes with imatinib in the erythroleukemia cell line K562

Sofie LustBarbara VanhoeckeMireille Van GeleJan PhilippéMarc BrackeFritz Offner

A1 Journal Article in MOLECULAR NUTRITION & FOOD RESEARCH

The impact of the initial ventilatory strategy on survival in hematological patients with acute hypoxemic respiratory failure

Pieter DepuydtDominique BenoitCARL ROOSENSFritz OffnerLucien NoensJohan Decruyenaere

A1 Journal Article in JOURNAL OF CRITICAL CARE

2009

Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or 'aggressive' lymphoma

Nam H DangMitchell R SmithFritz OffnerGregor VerhoefPeter JohnsonAma ZS RohatinerJohathan L KaufmanEva GineBertrand CoiffierMyron S Czuczman et al.

Chronic Lymphocytic Leukaemia

Jerina BoelensSofie LustBarbara VanhoeckeFritz Offner

A1 Journal Article in ANTICANCER RESEARCH

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

G HessR HerbrechtJ RomagueraG VerhoefM CrumpC GisselbrechtA LaurellFritz OffnerA StrahsA Berkenblit et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia

Jerina BoelensSofie LustFEMKE VAN BOCKSTAELEMireille Van GeleAnn JanssensLara DeryckeBarbara VanhoeckeJan PhilippéMarc BrackeFritz Offner

A1 Journal Article in LEUKEMIA RESEARCH

Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia

Sofie LustBarbara VanhoeckeMireille Van GeleJerina BoelensHeleen Van MelckebekeMary KailehWim Vanden BergheGuy HaegemanJan PhilippéMarc Bracke et al.

A1 Journal Article in ANTICANCER RESEARCH

2008

Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies

Dominique VandijckDominique BenoitPieter DepuydtFritz OffnerStijn BlotAnna K Van TilborghJOKE NOLLETEVA STEELLucien NoensJohan Decruyenaere

A1 Journal Article in INTENSIVE CARE MEDICINE

Spectrum of imaging findings in suspected multiple myeloma using dynamic contrast-enhanced and whole body MRI

Nele HerregodsK VerstraeteS Van SnickK GorleerV Van HendeFritz OffnerLucien Noens

Spectrum of imaging findings in suspected multiple myeloma usisng dynamic contrast-enhanced and whole body MRI

Nele HerregodsKoenraad VerstraeteS Van SnickKOEN GORLEERVANESSA VAN HENDEFritz OffnerLucien Noens

The anti-invasive and proapoptotic effect of xanthohumol : potential use in cancer

Barbara Vanhoeckemarc brackeJerina BoelensSofie LustFritz Offner

Bookchapter in Beer in health and disease prevention

The prenylated chalcone xanthohumol induces unfolded protein response, autophagy, and cell death in breast cancer cells by proteasome inhibition

Barbara VanhoeckeMireille Van GeleWim MartinetAnne-Sophie Vercoutter-EdouartSofie LustDelphine DebruyneDenis De KeukeleireFritz Offnermarc bracke

2007

A combined case report of 4 adult patients with hemophagocytic lymphohistiocytosis at the Ghent University Hospital in 2006

Tessa KerreE. SteelA. VantilborghFritz OffnerLucien Noens

B-CLL cells from lymph nodes express higher ZAP-70 levels than B-CLL cells from peripheral blood

Jerina BoelensJan PhilippéFritz Offner

A1 Journal Article in LEUKEMIA RESEARCH

Deguelin inhibits expression of I kappa B alpha protein and induces apoptosis of B-CLL cells in vitro

Ben GeeraertsBarbara VanhoeckeWim Vanden BergheJan PhilippéFritz OffnerDieter Deforce

A1 Journal Article in LEUKEMIA

Levetiracetam and bleeding disorders

Paul BoonR HULHOVENFritz Offner

A1 Journal Article in ACTA NEUROLOGICA BELGICA

Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia

FEMKE VAN BOCKSTAELEValerie PedeA JANSSENSF CALLEWAERTFritz OffnerBruno VerhasseltJan Philippé

A1 Journal Article in CLINICAL CHEMISTRY

Methylprednisolone downregulates ZAP-70 expression in B-CLL cells in vitro

Jerina BoelensSofie LustAnn JanssensJan PhilippéFritz Offner

Prognostic significance of lipoprotein lipase expression in B-cell chronic lymphocytic leukemia

FEMKE VAN BOCKSTAELEValerie PedeAnn JanssensFilip CallewaertFritz OffnerBruno VerhasseltJan Philippé

The endoplasmic reticulum: A target for new anticancer drugs

Jerina BoelensSofie LustFritz Offnermarc brackeBarbara Vanhoecke

A1 Journal Article in IN VIVO

Treatment of follicular lymphoma - A review

VANESSA VAN HENDEFritz Offner

A1 Journal Article in ACTA CLINICA BELGICA

Xanthohumol induces in vitro apoptosis in B-CLL cells mediated by non-classical ER stress

Sofie LustBarbara VanhoeckeMireille Van GeleJerina BoelensMary KailehWim Vanden BergheJ PHILLIPESmarc brackeFritz Offner

Xanthohumol: a new potential proteasome inhibitor that activates the pro-apoptotic arm of the unfolded protein response in B-CLL cells

Sofie LustBarbara VanhoeckeMireille Van GeleJerina BoelensJan PhilippéPetra Vinckenmarc brackeMartine PoelmanFritz Offner

2006

EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient

A JANSSENSM BERTHP DE PAEPEBruno VerhasseltNadine Van RoyLucien NoensJan PhilippéFritz Offner

A1 Journal Article in AMERICAN JOURNAL OF HEMATOLOGY

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

S CHOQUETV LEBLONDR HERBRECHTG SOCIEAM STOPPAP VANDENBERGHEA FISCHERF MORSCHHAUSERG SALLESW FEREMANS et al.

A1 Journal Article in BLOOD

In vitro screening for synergism of high-linear energy transfer Bi-213-radiotherapy with other therapeutic agents for the treatment of B-Cell chronic lymphocytic leukemia

Katia VandenbulckeHubert ThierensFilip De VosJan PhilippéFritz OffnerAnne JanssensC APOSTOLIDISA MORGENSTERNKlaus BacherVirginie de Gelder et al.

A1 Journal Article in CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgVH mutation status

FEMKE VAN BOCKSTAELEAnn JanssensAnne PietteFilip CallewaertValerie PedeFritz OffnerBruno VerhasseltJan Philippé

A1 Journal Article in CYTOMETRY PART B-CLINICAL CYTOMETRY

Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit

Dominique BenoitPieter DepuydtKoenraad VandewoudeFritz OffnerTom BoterbergCHANTAL DE COCKLucien NoensAnne JanssensJohan Decruyenaere

A1 Journal Article in INTENSIVE CARE MEDICINE

2005

Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis

R. SprengerM. SagmeisterFritz Offner

A1 Journal Article in GUT

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

E LEPAGEG GANEMTJ MOLINAG LAURENTM AOUDJANED ASSOULINEB AUDHUYM AZAGURYF BAUDUERE BAUMELOU et al.

A1 Journal Article in NEW ENGLAND JOURNAL OF MEDICINE

Baseline nucleophosmin status in mutated(M) versus unmutated (U) immunoglobulin B-CLL is a nuclear reflection of different signal transduction physiology

JENS BOELENSW. Van den BergheGuy HaegemanAnne JanssensJan PhilippéFritz Offner

Baseline nucleophosmin status in mutated(M) versus unmutated(U) immunoglobulin B-CLL is a nuclear reflection of different signal transduction physiology

Jerina BoelensWim Vanden BergheGuy HaegemanAnne JanssensJan PhilippéFritz Offner

Correlation of ZAP-70 analysed by RT-PCR with ZAP-70 determined by flow cytometry and with IgVH mutational status in B-CLL

Jan PhilippéFEMKE VAN BOCKSTAELEFilip CallewaertA JANSSENSFritz OffnerBruno Verhasselt

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

R MARCUSK IMRIEA BELCHD CUNNINGHAME FLORESJ CATALANOP SOLAL-CELIGNYFritz OffnerJ WALEWSKIJ RAPOSO et al.

A1 Journal Article in BLOOD

CVP plus rituximab compared to CVP alone in previously untreated patients with follicular lymphoma: Impact of baseline prognostic factors

K IMRIEA BELCHR PETTENGELLA RUEDAJ MCKENDRICKP SOLAL-CELIGNYFritz OffnerI BENCE-BUCKLERJ WALEWSKIJ RAPOSO et al.

Deguelin, a PI3K/Akt inhibitor induceds apoptotic killing of B-CLL cells in vitro

Ben GeeraertsFritz OffnerDieter Deforce

Documented and clinically suspected bacterial infection precipitating intensive care unit admission in patients with hematological malignancies: impact on outcome

Dominique BenoitPieter DepuydtRenaat PelemanFritz OffnerKoenraad VandewoudeDirk VogelaersStijn BlotLucien NoensFrancis ColardynJohan Decruyenaere

A1 Journal Article in INTENSIVE CARE MEDICINE

Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up

P SOLAL-CELIGNYK IMRIEA BELCHKS ROBINSOND CUNNINGHAMA RUEDAJ CATALANOFritz OffnerJ WALEWSKIJ RAPOSO et al.

Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (Review)

E VAN DEN NESTES CARDOENFritz OffnerF BONTEMPS

A1 Journal Article in INTERNATIONAL JOURNAL OF ONCOLOGY

Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies

Dominique BenoitEric HostePieter DepuydtFritz OffnerNorbert LameireKoenraad VandewoudeAnnemieke DhondtLucien NoensJohan Decruyenaere

A1 Journal Article in NEPHROLOGY DIALYSIS TRANSPLANTATION

Prognostische factoren bij B-CLL

Jan PhilippéANN JANSSENSFritz Offner

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

VH-gene usage is of prognostic value in B-cell chronic lymphocytic leukemia

FEMKE VAN BOCKSTAELEKaatje SmitsFritz OffnerAnne JanssensJan PhilippéBruno Verhasselt

Xanthohumol induces apoptosis in B-CLL mediated by caspase 9 following downregulation of bcL-xL and mcl-1

Barbara VanhoeckeSofie LustAnne JanssensJan Philippémarc brackeFritz Offner

Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism

Sofie LustBarbara VanhoeckeAnne JanssensJan Philippémarc brackeFritz Offner

A1 Journal Article in MOLECULAR NUTRITION & FOOD RESEARCH

2004

All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

N MOUNIERC GISSELBRECHTJ BRIEREC HAIOUNP FEUGIERFritz OffnerC RECHERA STAMATOULLASF MORSCHHAUSERM MACRO et al.

A1 Journal Article in ANNALS OF ONCOLOGY

Correlation of ZAP-70 analysed by flow cytometry with IgVH mutational status in B-CLL

Jan PhilippéB LEUSAnne PietteFEMKE VAN BOCKSTAELEANN JANSSENSFritz Offner

CXCL-12 induces prolonged erk-phosphorylation in Zap-70 positive B-CLL

Sofie LustJerina BoelensANN JANSSENSJan Philippémarc brackeFritz Offner

Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study

Katia VandenbulckeHubert ThierensFritz OffnerAnne JanssensVirginie de GelderKlaus BacherJan PhilippéFilip De VosRudi DierckxC APOSTOLIDIS et al.

A1 Journal Article in NUCLEAR MEDICINE COMMUNICATIONS

Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B

Fritz OffnerV KRCMERYM BOOGAERTSC DOYEND ENGELHARDP RIBAUDC CORDONNIERB DE PAUWS DURRANTJP MARIE et al.

A1 Journal Article in ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: A cohort study by the Groupe d'Etude des Lymphomes de l'Adulte

N MOUNIERC GISSELBRECHTJ BRIEREC HAIOUNP FEUGIERFritz OffnerC RECHERA STAMATOULLASF MORSCHHAUSERM MACRO et al.

A1 Journal Article in JOURNAL OF CLINICAL ONCOLOGY

Tangeretin synergizes with imatinib in inhibiting growth of bcr-abl positive K562 Erythroleukemia cells in an Erk-dependent way

Sofie LustBarbara Vanhoeckemarc brackeFritz Offner

Targeted alpha radiation and gamma rays induce distinct and mutation status specific transcriptional responses in human leukemic lymphocytes

S MARTINR KRONENWETTK VANDENBUICKEFritz OffnerS KLISZEWSKIC APOSTOLIDISA MORGENSTERNU STEIDLS RASCHKEF NEUMANN et al.

The restricted V-H-gene usage is of prognostic value in B-cell chronic lymphocytic leukemia

Jan PhilippéFEMKE VAN BOCKSTAELEKaatje SmitsFritz OffnerBruno VerhasseltANN JANSSENS

VH-gene usage is of prognostic value in CLL

Jan PhilippéANN JANSSENSKaatje SmitsILSE MOLLETFritz Offner

2003

Alpha-immunotherapy compared to external gamma irradiation, cold antibody and chemotherapy in B-CLL in vitro: Correlation with clinical chemotherapy sensitivity

K VANDENBULCKEFritz OffnerFilip De VosA JANSSENST NIKULAC APOSTOLIDESR MOLINETW JANSSENSHubert ThierensRudi Dierckx et al.

An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma

R MARCUSK IMRIEA BELCHD CUNNINGHAME FLORESJ CATALANOP SOLAL-CELIGNYFritz OffnerJ WALEWSKIJ RAPOSO et al.

Cold and alpha-conjugated anti-CD20 induce different in vitro apoptosis reponses in B-chronic lymphocytic leukaemia (B-CLL)and splenic lymphoma with villous lymphocytes (SLVL)

K VANDENBULCKEFritz OffnerGuido SlegersFilip De VosVirginie de GelderA WILLEMSS MARTINR MOLINETC APOSTOLIDISTK NIKULA et al.

Cytotoxicity of gamma versus alpha radiation in lymphoid cell lines with defects in the TNF receptor family mediated and NF-kappa B related apoptotic and anti-apoptotic pathways

KJ VANDENBULCKEK VANDENBULCKERudi BeyaertC APOSTOLIDEST NIKULAW JANSSENSANN JANSSENSVirginie de GelderAnnick WillemsGuido Slegers et al.

In vitro evaluation of Bi-213-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage

Katia VandenbulckeFILIP DE VOSFritz OffnerJan PhilippéC APOSTOLIDISR MOLINETTK NIKULAKlaus BacherV DE GELDERAnne Vral et al.

A1 Journal Article in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

In vitro evaluation of Bi-213-rituximab versus external gamma irradiation for the treatment of B-CLL patients: Relative biological efficacy with respect to apoptosis induction and chromosomal damage by the micronucleus assay

K VANDENBULCKEFilip De VosFritz OffnerJan PhilippéC APOSTOLIDISR MOLINETTK NIKULAKlaus BacherVirginie de GelderAnne Vral et al.

Molecular mechanisms of alpha-particles-induced cytotoxicity in human leukemic cells as revealed by gene expression profiling

S MARTINR KRONENWETTK VANDENBULCKEFritz OffnerS KLISZEWSKIC APOSTOLIDISR CARLOSW JANSSENSM LEROYT NIKULA et al.

Prognostic factors for aggressive lymphoma patients treated with front-line autotransplantation after complete remission: A cohort study on 330 patients

N MOUNIERC GISSELBRECHTJ BRIEREC HAIOUNP FEUGIERFritz OffnerC RECHERA STAMATOULLASF MORSCHHAUSERM MACRO et al.

Radio-immunotherapie bij B-CLL-NHL: een update

F GEMMELF DE WINTERK VAN LAEREV RENARDB BRANSRudi DierckxFritz Offner

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

2002

Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells.

Tessa KerreG DE SMETM DE SMEDTA ZIPPELIUSMJ PITTETAW LANGERAKJ DE BOSSCHERFritz OffnerBart VandekerckhoveJean Plum

A1 Journal Article in BLOOD

Alpha-immunotherapy compared to gamma-radiation, cold antibody, and chemotherapy in B-CLL in vitro: Correlation with clinical chemosensitivity

Fritz OffnerKL VANDENBULCKEF DEVOSANN JANSSENSJan PhilippéGuido SlegersHubert ThierensT NIKULAC APOSTOLIDESW JANSSENS et al.

Cytokine deprivation improves the homing of long-term cultured human hematopoietic stem cells after intravenous injection into NOD/SCID mice

Tessa KerreKatrien VanheusdenFritz OffnerJean PlumBart Vandekerckhove

Cytokine deprivation improves the homing of long-term cultured human hematopoietic stem cells after transplantation int NOD/SCID mice

Tessa KerreBart VandekerckhoveFritz OffnerJean Plum

Definitions of infectious diseases and complications after stem cell transplant

C CORDONNIERD ENGELHARDP LJUNGMANA DEKKERP DONNELLYH EINSELEE HOLLERH LINKA LOCASCIULLIR MARTINO et al.

Efficacy and safety of Rituximab in B-cell post transplantation lymphoproliferative disorders (B-PTLD): Preliminary results of a multicenter, open label, phase II trial (M39037 TRIAL)

S CHOQUETR HERBRECHTG SOCIEAM STOPPAP VANDENBERGHEW FEREMENSA FISCHERF MORSCHAUSERG SALLESE VILMER et al.

Long term culture of human hematopoietic stem cells influence on homing, organ selectivity, survival and proliferation early after transplantation into NOD/SCID mice

Tessa KerreBart VandekerckhoveFritz OffnerJean Plum

Radioimmunotherapie bij het B-cel Non-hodgkin Lymfoom: een update

F GEMMELF DE WINTERKoenraad Van LaereB BRANSV RENARDRudi DierckxFritz Offner

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

2001

An adapted NOD/SCID model supports the development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells

Tessa KerreBart VandekerckhoveFritz OffnerJean Plum

Both CD34(+)38(+) and CD34(+)38(-) cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion.

Tessa KerreG DE SMETM DE SMEDTFritz OffnerJ DE BOSSCHERJean PlumBart Vandekerckhove

A1 Journal Article in JOURNAL OF IMMUNOLOGY

Comparison of in vitro apoptosis induction by alpha-irradiation versus gamma-irradiation in B-CLL

Fritz OffnerFilip De VosK VANDENBULCKEANN JANSSENSR MOLINETC APOSTOLIDISW JANSSENST NIKULAChristophe LahorteB BRANS et al.

Essentiële thrombocytose.

Fritz OffnerAnn JanssensJ VERMEIREN

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

The behavior of long-term cultured human hematopoietic stem cells early after transplantation into NOD/SCID mice provides explanations for their impaired long-term engraftment in this model

Tessa KerreBart VandekerckhoveFritz OffnerJean Plum

2000

Bone marrow necrosis.

Ann JanssensFritz OffnerWerner Van Hove

A1 Journal Article in CANCER

Both human CD34(+)38(+) and CD34(+)38(-) cells home specifically to the bone marrow, but show different kinetics in take and proliferation

Tessa KerreG DE SMETMagda De SmedtFritz OffnerJean PlumBart Vandekerckhove

CEA elevation in chronic granulocytic leukemia.

M WITHOFSFritz OffnerP DE PAEPEMarleen Praet

A1 Journal Article in BRITISH JOURNAL OF HAEMATOLOGY

Generation of T cells from adult human hematopoietic stem cells and progenitors in a fetal thymic organ culture system: stimulation by tumor necrosis factor-alpha.

S WEEKXHW SNOECKFritz OffnerM DE SMEDTDR VAN BOCKSTAELEG NIJSM LENJOUA MOULIJNI RODRIGUSZN BERNEMAN et al.

A1 Journal Article in BLOOD

1999

A single step real-time quantitative RT-PCR reaction for detection of the BCR/ABL fusion product

H VAN LIMBERENL VAN DE LOCHTBruce PoppeAnne De PaepeFritz OffnerE MENSINKFranki Speleman

Bone marrow CD34+ cells generate fewer T cells in vitro with increasing age and following chemotherapy

Fritz OffnerTessa KerreMagda De SmedtJean Plum

A1 Journal Article in BRITISH JOURNAL OF HAEMATOLOGY

Chromosome 7 short arm deletions and disease progression in CML

Bruce PoppeH VAN LIMBERGENANN JANSSENSNadine Van RoyBarbara De MoerlooseJ PHILLIPEAnne De PaepeFritz OffnerFranki Speleman

Identification of a novel CBFB/MYH11 fusion in a patient with AML-M1 and a t(16;16)(p13;q22)

H VAN LIMBERGENB VAN DER REIJDENBruce PoppeFritz OffnerNadine Van RoyH DAUWERSEAnne De PaepeFranki Speleman

In vitro intrathymic differentiation kinetics of human fetal liver CD34(+)CD38(-) progenitors reveals a phenotypically defined dendritic/T-NK precursor split

Jean PlumMagda De SmedtBruno VerhasseltFritz OffnerTessa KerreD VANHECKEGeorges LeclercqBart Vandekerckhove

A1 Journal Article in JOURNAL OF IMMUNOLOGY

1998

An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome.

DW DENNINGA MARINUSJ COHEND SPENCER HERBRECHTL PAGANOC KIBBLERV KCRMERYFritz OffnerC CORDONNIER et al.

A1 Journal Article in JOURNAL OF INFECTION

Anémie bij de kankerpatiënt.

T KERREFritz OffnerWerner Van Hove

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

De ziekte van Waldenström.

A MAENHOUTFritz Offner

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

Impact of previous aspergillosis on the outcome of bone marrow transplantation.

Fritz OffnerC CORDONNIERP LJUNGMANHG PRENTICED ENGELHARDDirk De BacquerF MEUNIERB DE PAUW

A1 Journal Article in CLINICAL INFECTIOUS DISEASES

Risk mortality related to duration and severity of neutropenia following bone marrow transplantation

A2 Journal Article in TOPICS ON SUPPORTIVE CARE IN ONCOLOGY

The Hermansky-Pudlack syndrome

A BRANDTFritz OffnerJ QUATACKERJ PHILIPPEFrançoise Meire

A2 Journal Article in Bull. Soc. Belge Ophtalmol., 267, 99-105

The role of interleukin-7 in early T-cell development.

Fritz OffnerJean Plum

A1 Journal Article in LEUKEMIA & LYMPHOMA

Two cases of disseminated mucormycosis in patients with hematological malignancies and literature review.

I CUVELIERDirk VogelaersRenaat PelemanDominique BenoitV VAN MARCKFritz OffnerK VANDEWOUDEFrancis Colardyn

A1 Journal Article in EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

1997

Hematopoietic growth factors in cancer patients with invasive fungal infections.

A1 Journal Article in EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Phenotypic and functional maturation of TCR gamma delta cells in the human thymus.

Fritz OffnerKatrien Van BenedenV DEBACKERDominique VanheckeBart VandekerckhoveJean PlumGeorges Leclercq

A1 Journal Article in JOURNAL OF IMMUNOLOGY

The use of hematopoietic growth factors in cancer patients: indications and impact on invasive fungal infections

A2 Journal Article in Eur. J. Clin. Microbiol. Infect, dis., 16

1996

Acute lymphoblastic leukemia as part of the retinoblastoma inherited cancer syndrome

J VAN DROOGENBROECKLucien NoensA JANSSENSFritz OffnerWerner Van HoveFranki Speleman

A2 Journal Article in Belg. Hematol. Soc, pp. 90

Idioathische trombocytopenische purpura bij volwassenen.

A JANSSENSFritz OffnerLucien NoensWerner Van Hove

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

Mortality hazard functions as related to neutropenia at different times after marrow transplantation

Fritz OffnerG SchochLD FisherB TorokStorbPJ Martin

A1 Journal Article in BLOOD

Prognostic markers in septic shock

Jan PhilippéFritz OffnerGaston BaeleGeert Leroux-Roels

Splenectomy does not influence dose intensitivity of chemotherapy in advanced Hodgkin's disease

Fritz OffnerR PIENSAM GOBERTN COPPENSLucien NoensWerner Van Hove

A2 Journal Article in Belg. Hematol. Soc, p 99

The use of hematopoietic growth factors in cancer patients: indications and impact on invasive fungal infections

A2 Journal Article in Europ. J. Clin. Microbiology & Infect. Dis., 15. Suppl. 1, S1-S8

1995

Aspergillosis prior to bone marrow transplantation : is it a contraindication to BMT?

C CordonnierJ BeauneFritz OffnerA MarinusP LjungmanF Meunier

A1 Journal Article in BONE MARROW TRANSPLANTATION

Behandeling van chronische myeloïde leukemie.

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

Chronisch lymfatische leukemie.

Fritz OffnerA JANSSENS

A2 Journal Article in TIJDSCHRIFT VOOR GENEESKUNDE

Intensive care treatment for patients with hematological diseases

K VANDEWOUDEA KOCHDirk VogelaersLucien NoensFritz OffnerF COLARDYN

A2 Journal Article in Belg. Hematol. Soc., p. 108

Retrospective analysis of different therapeutic options in treating adult ITP-patients

A JANSSENSFritz OffnerJ VAN DROOGENBROECKLucien NoensWerner Van Hove

A2 Journal Article in Belg. Hematol. Soc., p. 135

Sepsis and other severe complications of hematological disease in a medical intensive care unit

K VANDEWOUDEA KOCHDirk VogelaersFritz OffnerLucien NoensFrancis Colardyn

1994

MORTALITY HAZARD AS RELATED TO THE DURATION OF NEUTROPENIA AFTER MARROW TRANSPLANTATION

Fritz OffnerG SCHOCHL FISHERP MARTIN

RELATIONSHIP OF SERUM CYTOKINES (TNF-ALPHA, IL-1-BETA, IFN-GAMMA AND INFLAMMATION MARKERS (NEOPTERIN, BETA-2-MICROGLOBULIN, C-REACTIVE PROTEIN) TO TRANSPLANT-RELATED COMPLICATIONS AND IMMUNOGLOBULIN PROPHYLAXIS FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION

KM SULLIVANFritz OffnerM HEROLDM MORIC HUBERD NIEDERWIESERFR APPELBAUMR STORB

1992

GRANULOCYTE ELASTASE, TUMOR-NECROSIS-FACTOR-ALPHA AND UROKINASE LEVELS AS PROGNOSTIC MARKERS IN SEVERE INFECTION.

Jan PhilippéG DOOIJEWAARDFritz OffnerP TURIONGaston BaeleGeert Leroux-Roels

A1 Journal Article in THROMBOSIS AND HAEMOSTASIS

INCIDENCE AND CLINICAL CHARACTERISTICS OF PRIMARY GRAFT FAILURE

Fritz OffnerB SANDMAIERB TOROKSTORBP MARTIN

The relationship between TNF-a and liver failure

Jan PhilippéFritz OffnerGeert Leroux-Roels

A2 Journal Article in Eur. Cytokine Netw., 3, p. 253

1991

Analysis of whole-arm translocations in malignant blood cells by nonisotopic in situ hybridization

Franki SpelemanK MangelschotsM VercruyssenP Dal CinA AventinFritz OffnerGenevieve LaureysH Van den BergheJuliaan Leroy

A1 Journal Article in CYTOGENETICS AND CELL GENETICS

Extra translocation t(lq9p) is a prognostic indicator in myeloproliferative disorders

G RegecambrinFranki SpelemanS KerimP ScaravaglioF CarozziP DalcinJL MichauxFritz OffnerG SaglioH Vandenberghe

A1 Journal Article in LEUKEMIA

Fibrinolysis and coagulation in patients with infectious disease and sepsis

Jan PhilippéFritz OffnerPJ De ClerckGeert Leroux-RoelsDirk VogelaersGaston BaeleD Collen

A1 Journal Article in THROMBOSIS AND HAEMOSTASIS

Serum TNF levels in patients with infectious disease and septic shock

Fritz OffnerJan PhilippéDirk VogelaersGaston BaeleFrancis ColardynM BaudrihayeAlex VermeulenGeert Leroux-Roels

Bookchapter in The year book of surgery 1991

THYMOMA - A CLINICOPATHOLOGICAL COMPARATIVE-STUDY OF 25 CASES

Fritz OffnerJ VALLAEYSHendrik RoelsM VANDERSTRAETEN

A1 Journal Article in EUROPEAN RESPIRATORY JOURNAL

1990

In-vitro production of cytokines in blood

Geert Leroux-RoelsJan PhilippéFritz OffnerAlex Vermeulen

A1 Journal Article in LANCET

Serum tumor necrosis factor levels in patients with infectious disease and septic shock

Fritz OffnerJan PhilippéDirk VogelaersFrancis ColardynGaston BaeleM BaudrihayeAlex VermeulenGeert Leroux-Roels

A1 Journal Article in JOURNAL OF LABORATORY AND CLINICAL MEDICINE

Wegener granulomatosis : a review of 5 cases

N VeysFritz OffnerN Lameire

A1 Journal Article in ACTA CLINICA BELGICA

1989

GM-CSF and G-CSF in hematology and oncology

Fritz OffnerW Vanhove

A1 Journal Article in ACTA CLINICA BELGICA

1988

Influence of blood-collecting systems on concentrations of tumor necrosis factor in serum and plasma

Geert Leroux-RoelsFritz OffnerJan PhilippéAlex Vermeulen

A1 Journal Article in CLINICAL CHEMISTRY

Onderzoek naar een aantal prognostische markers bij patiënten met zeer ernstige infectie of sepsis. 8e Amstol Symposium, Amsterdam, 25/9/1992, werkboek p. 3.4.

Jan PhilippéG DOOUEWAARDFritz OffnerP TURIONGaston BaeleGeert Leroux-Roels